PBOS

Kubota Vision Initiates PBOS Prospective Study in Patients

Retrieved on: 
Martedì, Gennaio 18, 2022
Optical, Health, Clinical Trials, Medical Devices, Research, Stargardt disease, Patient, Severe cognitive impairment, Cornea, Retina, Hope, Eye surgery, Diabetic retinopathy, AMD, DME, CEO, HIV disease progression rates, MHealth, View, All India Ophthalmological Society, Society, Artificial intelligence, Company, Association, Hospital Insurance and Diagnostic Services Act, Pharmacology, Doctor of Philosophy, MD, OCT, Optical coherence tomography, Glaucoma, Association for Research in Vision and Ophthalmology, Hospital, Physician, Medicine, Medical device, Medical imaging, Ophthalmology, PBOS, Kubota Vision Inc., PBOS, KUBOTA VISION INC.

Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT*1) device.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision or the Company), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT*1) device.
  • The PBOS operates on the same principle as OCT devices used at hospitals but is developed so patients can operate it by themselves at home.
  • Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.
  • https://www.kubotavision.com/ ; https://www.kubotaholdings.co.jp/en/
    Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Kubota Vision Demonstrates 3D Imaging Capabilities Using AI on PBOS

Retrieved on: 
Mercoledì, Luglio 29, 2020
Mobile, Wireless, Technology, Medical devices, Other Technology, Software, Biotechnology, Pharmaceutical, Health, Data management, Optical, Medicine, Optical imaging, Medical imaging, Kubota, Optical coherence tomography, Companies, Tomography, Equipment, PBOS, Kubota Vision Inc.

Kubota Vision Inc. (Kubota Vision), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company demonstrated 3D imaging capabilities using artificial intelligence (AI) on our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device.

Key Points: 
  • Kubota Vision Inc. (Kubota Vision), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company demonstrated 3D imaging capabilities using artificial intelligence (AI) on our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device.
  • The first fully-functional, working PBOS prototypes have been completed, and the company is currently in the process of further improving the software including 3D imaging capabilities.
  • Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, We are excited to share this great news that our PBOS demonstrated 3D imaging capabilities using AI via internet data transfer.
  • Kubota Vision, the Kubota Vision logo and Kubota are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.